NCT01364584View on ClinicalTrials.gov

Impact of Exenatide on Cardiovascular Exercise Performance in Type 2 Diabetes

NACompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Type 2 Diabetes
Interventions
DRUG

Exenatide

Subcutaneous injection 2.5 micrograms (mcg) to 10 mcg twice per day (BID)

DRUG

Placebo

Subcutaneous injection 2.5 mcg-10 mcg BID

Trial Locations (1)

80045

University of Colorado Anschutz Medical Campus, Aurora

Sponsors
All Listed Sponsors
collaborator

Amylin Pharmaceuticals, LLC.

INDUSTRY

collaborator

Eli Lilly and Company

INDUSTRY

lead

University of Colorado, Denver

OTHER

NCT01364584 - Impact of Exenatide on Cardiovascular Exercise Performance in Type 2 Diabetes | Biotech Hunter | Biotech Hunter